y_80?mBLʴtbڧ@vIl'6ے@y!H::::뛷|ot(=YA(}N$ĝLauY$3/( d$e?uu9fG7G< fa·t'N*7nS?X>e2E+?AW \}7]ħ/c5&nHgnPcbDn,uiv787MЛ{WaAWzh|1묛_5ۼ,7C;]Y~ਫ਼uz-hl㤛}= I4 -ڍn֙Im{b|xzՋyy ӻW!x+m?~HWj䨧Y?׺PMvl{_z39"sW7if mh"iߣݰu~ލga4it fio0m| a_ot˶Z؄U7gz/O#L7*<<U,Ӳ_i{;18n>N[qp{^8# <'LC;i @5^w5Cq3XӅQ,`'Oa޳MURUE ᦖzZT)zz3<@ʀ+uQkU1D'8_g:OWmFOUbpXtwN6 xND "i-ﻳjF>] _+v/Cd얃)~/o[F6NԃD_$sq 4T/{ćspz,HAk`[)Xgs|=kV=9b4-OuМ'Y *?'5'?}\M~^~>^^էWP`ӣoGm^4<^OѧOWw^}j|>|?|8=l4@鳛_߿:Fف"d_V#0 /F#ԋ!R`uMF׽tc.9^Lp+X&3n `d{^ݾ4y޼hܾnqCOX_TWfϧ>_gW/ێk¹ۿ{qfΐ8Kܻ]ptLvDd=%hL7 Z9إx ]xcRQ<~ U7j8"KUy Qhwz9u,O[f0eyNz>@1Q/q鍝Ah#/O[xo >́BGs h>aw7RUp|3r ):h^޾rWcuj0d7K^`г=q7w—Ij5vzz?DDyp;T*^|Po>×.n0Ӌdp}mw>\ ^n@&&$pdC9Jvv:JkJN^oZSi1lޟ緯F})-h5gˣ*< [nޟۣgCut,ޢl7@gHTq}q1r_l/Z5_*Ŵl[w[%$قilsQgaYz}U|ܟtEa݄-6SRGԿ>[2Vy3w8T;Ço㛳侉bwspc\|!wԆSu]l7"=?O[`.d>6>}ξ_[׃eOB t<\܁!>?L hݱ3CrL[#Oun8y@oO%@!mM%@;C˻![)-؍5 5h?mmo/a jӰ'H?S?bƛOdvZ "`{|ZSx߾ܢ! |B]S|{5$hy^ma+OGx ]Cp\cy)3(uAD]LZWU )m"= G3?̈is(]890-Ru'E)wj [^)g+DUN!D";Z}uVBVQ%O#XSHGd ,J+c&U<`J)d rBIA0:ZZE<%[1׾1)6~l7Ҥun1rZ^.-v e.3F1,HhzpTο}Ro!B!#@,wp)+[/wMGs]mփޠ"{ϿAvh]zsB6ltAlN_[GLJޛz1G${>oݲ&jESyM,GŁ7ݿQ{p`r¥zAUї7^LQ} M/Öu`E> d~hb`⟥M ѿ ߫աG(Wr>S͏N|Kwo~OW~G yܛ^kIz\Wgei" 0Φy8Pxe!ӿ >r/O%S"ʑkI}0$8U{ί~#y_7H464_o/lUa.Bxhr ,#.`s2"@ ;dpo"tDB̍e[;| og?rF?~p:/"POFq'do_!,Ӌo0f2Hh8dmƓ.b/?_.>&J/#׫!ݥ~+$ #;=dVDQ:wj!XsC|zU^{+}A;L4<&X rnGx ԽQ\m DB(Gp)2B'D` +`Eh2S5@ $ʗBڼ]f`ТcK;t{;@ůؙ<2HZ,1(X~߾ղataP=p_dJ "(waAW5UDJmDKH3 !S(tNnDeKԺts|.Tp޼kK] fzR26AZoTۥ+(P]g!Vh8,T&2H41-;䓫@uJ"(4Y"׋LEVI<+^H˳}}M}:OrQk.e_m1yȋQ0+Zֳ~#PQb_>Wfw;8Z \>L׌cߑvCOA0.MkNwvwp^din`cn3~{@A<<~3/>h";ez;q0dewKVbyЉt1Y4n5.Dۂw1yp^Xm&$~1%#Ge}{;1 >~lL~U bPvTv8q1nƗ1\|K?]]4/goo^qpl?~ǩ{{wݾ}5?xws_}qm0lWۋ yS~sKkS~1/A<9]n_-^Gj_fo/OͷzyvpJMj?&TS=oo_OE Q7bc^<]H?$?o_p\wvm\K5c.I־?2MFw6< }S η׬ݔ.G`?n5>* .M!pؙ^\tnmվm>/6Ҍ>AqTß~9Ylmkᓷo϶7ߖcWϷۇwmlH٧oڬםۑ_zpexN^Ƣqӻw4<~+ F|n>pZ=}y,q}:X^_oη{ip51@tWF|?_2:mޚ{\w||NF|x{7:@䫱_;}?|i>{u|u4ikAGpuy>FtPS_ﷇ?a}g>׼4foFPSeOS?u|x9yuzc}o_mL_<4 ; ozp|ܞl@X_HwyH!=<{QI?ڵ''3~}xvspl;ip׌tW6}k{K|{C\V? ?޾LhponϽ7}!xxp4m^nxr?u^_<_~y}go}l]~noO'߾w1^|~ټ1_߽tϫw7_/QHg?O#BWaL>}v.no?4߿ťw]|pxL_'G|t~239_wY7NRhEyp28h=k|wο؋{ʗ_}u0 OwשQWft^uCӧoo3ř?ߏmt9{Nwξ]: N/7adv+I&<:o\%>ޝݷƇo-A̩i:_| $|}i{_^z}]:TpԇC'so{؎ߙO=ܽ w߃_k\_pniK8͋ӷG/ywq޼zVut޿͎ճwҷ />4GOQ:7^}[BK^4ۻZ|~;R_;/'Io$>ۜ}|z ՗އ%uQ27kO +/>|3^iTJdzAc[w0H>W׃ Qw~0epuvxx~|4ۛw};pZ ˯óai%R)x}R%`E^5lh7?Ķ d/ :`A:W/'=LLg7NdL8)VGn]",얚wfhUvas]_}.y%'}UN5> e^Us0b yPbJ-ׯo/ ڞ}{,ooorT1%y`\hJ`4jx'e5ɯ^$;x&t Xڶp/q8bd3]4yK壜3S]4Dd9]9̜V`8L "wR< .7gJMl}rl?޶\KXowAN.pK&< *o9y;M/,\`ULZ*UB"ޔg}YH\el2G Ɉ53 [7+Px)ࣰ>Ws׋,3Xl&\:ſn{pq&'܈_Q]}b{ >EzZi+??TM*eNSlswAޱ+طw& Lr8P\3ߊȧt2KwQ|y7 {z?~ޛw%g::h@gw)t^=&[~_Ƥ0N~Gһڥ͆H*œ I)tWf{:$X%2+,{A7p{`+/jVm0I&AP8_u?QWIK"KX_zphp{!iSi/66W747}/qCչss$P뵤UsFwUt|RoNN$vojޏDBQGAX1:MMJV1gԠzV, =W?M;j83cT}g5{{%Ff zۉeo٪ zaw(<ɢיOMEm9eò&ivo1)̻ZG2_[5_QKOf0N"Mh(VW^搪 I BwPg'Un4$iII{ 4h5qyN& S/f+Xi#|;eޘ1T{Z gѴ;ȏ^XshG܍aw &C괾{EF]?J#;ƺS68G;n.]QHmdkgY:|o"_^4f*jz4 peo~KoR߿;.|WZ hIҫׯ5 ޝg=vӀQ͝W4qfic {rka*tR-Iu,l-K9evMY{/PuM@yQhT[3y1V}c`iC/ci0H;Ad8zV6 mV@\g#+|R,D,J=+P{o9Dy0)`h J>N ͣ`IvXK&'(e4U۶L4,\?뙾uFZ-,cXM%Ղͼ ˠN{ןf0wC;3S?\ e "ˤ4D>_.@;c8M](H<݄e:eۃ!Ī/8nҚK~sXF(Z~_,kckM«OWwATSƉ $^ڦ$'1n*N6["&ݬOBG.9-:%r횛Buu1ݕ:Жrϭ7 kXLfV6މڮ ^w͞;bX`bހ4 F?eQOrjM95֒3z6]rUXYE2cyK+{̍h؞3>@ף~>,MIV2X9K&v*!{ zͳd[߬gFb#+ e mljL`]@e$؍ߧ_;?|BIqʪ`5w |ɔXW1Ĭz5˫ !v-,dkXc%@q6]̽\o8 7@ '`k/;*u R%/[m$n&ĿC~ݤFWu84PFuT Sʄw?өO2̼6$?='?S^żIW` COP*/IA(G\!Zx(hj!;`M gekaMtd [I Uȟ`q~Ӌ?iTu DE\$r`rkѺTSж\mhDY`)+!¾;/ٺۛm#7lM{U+pp0v68mI2M]#P0ó"`^a&]=pRhj¿KEG;fr ѭ6'h?^S5Wvo`,azBiZzab>!Zw,";ail>u 1T(V "QCPyw!,xاγUiP`7^#nU`vaydK1W!g3""Gs3%|D!&° {dt"R$2?Hg"UhKWQȒ  +kUD)"ĬT P rUWIh=Au o0f"w ȍ0XSZE+*8رrVc9b6UX0X.܍U1t+'Q=0yBCm)R¹Y !Qiy˅sϝ A)sJB0n;0RQTN 0nFeYoleSآ(2oꝺ*jUeO(vVa ,"5ta8^_ \pRY4&z/ YF+d \ l~UA`o DZu]-Hߵrjv& 񴓢ЁQH,bo CD{"*C⧜NaW)N;[+jUK]32W);JMMAk,%W( IS~\!}h6Wn.axpXyܥ*2stt0X`f ayq3Kw*:cGN德JtyQp A8lt ke*X x;3^Nݣ؍c+RPMxm j♱4%-\F-nNԱrjO.*&ln2!PnߝFÁtfgޠ~='zDAF;4ǹTNMM"HEN '.Z'i `x&*=n6e8ȁMR ,-8l=u?pׅn؂4[+c9D&Ghj:6qF])/a쫇WXT K]8]̜`k 0Ǜ3ò63vp& QVeZ0 p"ڵM,R.tu.6y섮д R] 7ҹogx~vj4r5懗AܙRviu\aQ%Nk( Lƻ5_[ơ=G'T1yB.?'AuI3gcm|j˩NL%#U4*5)oSZNuJ+\/p GOVc, }z oI\dMGj:K@-.bhNt#m:kl5Ks2[.N/ljfLQ4ռK.4 r"nՑyV(Q3b.Z ׁ\(3Xӧf!zBQg)RL67.2v7"1ji`uzq{8~x#-xf2j㷲?#\1?dyj ,7׃F<0܌l^#, -@43E 0] }UxMm&Rs؈'?Xۼ+Xm{p r7wxE^-̷jw=enbtMМC4ᖉn(jt:|͉<{z!jfy'ꆃ -uo{'(S~e+* -Yvys{(fkc4f/eg 3ڵ*h-%?/;7\(HOSgN WPzI("n6 tRUߵh0;ݾmcS;?.UPL) 1uu'TFUj!5^onu9ݮK9ϖxE-Sč „{ M-rk D,7==  uQB_ϝBD` Sx^ט}|މv; (pWK<\X<$,e]jZVo6&`ywd^yd7bz-MZT#JQʁUvO}P`GYgMz.P-㞙jY긾*4'ذ;0Fnͷ_84QGz6F7P&]=oƮh4̣}yBU+WfU#,{Coڛ~W-o ]g⡐KƖFGsun0L ޮt*7'u%|+!oagjDR!ȳS3*iFU +o[qATgHEM+N (Cr*](Nf51O OSY)F{?  y^$^{Ya6_FH_ n}K3 +Q,U,;C–JKo%yL$|p}#4}0LVX )&YGeGIch2D \8" ZҊ ,5@%)7W-{E>h n`ě&ҲzhtVXlCjݙ5 M69muvģ/¼%0C*KocOF^VCOez"D$1?;`6v6ęfޝXzS7ڵ\׍돬Qv”8Rt&\DH`H ?ͩ8]A:sG &QK}O6TRrKµbaLh/$U=IRZU ΢TI"vh%`R&wʑ BjGbGk]aIIJJuIB47ȼ*|sy$Up^dN UE&賅K{Gb4‘w5`- -: yB+Z`Pfol3O MGfI!6#dqzWGx?t]uxn92ף!!$3IJ1? ㈓|FHYCQO&Ap(c?fؐ h?&!%2JFE47a b曟iW^CS -~釹 s; T&9wn6Mo&)ȴ67gz\NԵBdFl`>ll :vr #u *$}xqGd#uA8dA-bH+î,:4BOGN!ORh7u? >}N04v0:.1t:#G/D$6gSoF )1_9nԡw0mA!+8ƦaUu.[h8+&v\NA|urK2J+K)zd4[2oTtCa/(@x~g/@mnHV C7&k4qM1 ۝.{6v`؟ᴀ{Ù6Qr T!3³ʵ$`O #R3*OPe1p͖B[- :|-wHbiR$=N@̓LH[.\^Qمۭ^p{,FVWM!%TgJ׻Yv|q|TUz!z `Ub8N@D!a bGQ&A=bHiP&]GX=hpnFԫ[QT ᗩz񕮥fj'~*,f>_39JEK^U@A^6߳'*&n'AaN{D[ bGei,ҔUog_ hH >N++Ƃ_㪫Jeܙ)r433dЍO*)iAOIA2QNqWf M_Iݑ@}Hd) \6HLOiIxi L7$G:`imVpƃsƋ-q*4=A Tl24~< +8lTߪ=$prz9'au4mF:sC6Ul3V}H${khVk(CMNܬys4(+jK  QBSs; ķroѠ7Ri7+jnԩ(hNo@8тRB74{$RP]HYyO`l@vlHFǘ g`,%JsR&, +{%Tf jDPRϥ%DvMT,o Ng@A< -qP?dfd.!囝+T'Tfp˥6|W\Ffro)ӆSB97*;fiBsr-p], RBRPȠUoP!8m" 0U,] oί7C C)rN3v5HuJS׻AE>xJuE) +=Y!CXJƹBd]@ &i VQQ 0KM3J<3 )[OD/ J?7W8e􈊆xQE̍+,=:u] :˩Ab-(|ebaGeё%GZ7aDpϒ{ ʘM.D5D27LoLF"<ԋ̤Y8s־b$?ߦ ](UFn$#W'42|e h4P"wŃOUT~a>*1ExxaCk39jUedETSj8/$"o=5AU+V|RJL-F _dPz^\--hn$|" L%'Ъz@R&W{/_Hغ wf<ޢ`„Ap̓w{۫ bio]694§/XBVEpId0:VsgG|S6$t(;U GwI tNTKoh,A1i|̵[aS/-ӄG)4bWD$͑B'n=kË9 /!܉[y/ Z.-W1&:b@/rqZ|\pGȚ鞀lܡp>| L\M-9K.-Ex7]W˱v070؛(dmjܕVFG1ej6Gulo( {TIb^ sMSF 59\st[+1{)َ'[el׀3tz:Bea!$ #d t|}*Bǀ%9"{{57ڸQtRY3tۻ; " v9WJXHGs[p~X2nBv=뵸IT?'DZ+Key,T(L۶c O [pP} U,D*b첥e# Q9bu"1TJxYĈQYD-hbq;1Yԋ\fr,RzsIOI/#"Z4t,u5b:Kg+1ʉsg64cbREAyRb@ϮM- kiGdy;(2-.3 )MVmɵybD GfKxS5|pbeƏ$¸q.4 |a*_/Khw_]WLNRRPQZ3-kI]>%?잔[T{~DY]JK%l--Ko-;ipAGNdz;CYدjÒ'nط'"kSYd#] S7wn /]?nЗH ^i,_ѐh[_ZEFNtG]0RԡUYFacnArO Q,,a\s5Ur7Q^2tY̜M=U:*( < %z:Q %N kcs=y{a3*'6A{!,E4yo6`މa {{cWo%̝XN5Kuv'EfYs(p:Qެm1M*._vebztbIط˕ ( i>#_?]aTyQDHd?p0G3\M#f4a8s(]d`Zn+v3E2q@]))t`"w "aߥz +N^D/DL6J)J۳OId8sƙ5hp:feRuc$Yg% B,7Iu.' m`_hcpS;icEHÃS.:vXGr>ˌMGF0k``]c5`򝾞x6 kܕ={DGXkf訴Vvę &,*vmi8]q!{]u :Y;Wþ3A AXGob&go{{{TJ0qTpZ5FM`ԈȈwcϭ(`ZƅmIAMCwW|3h݄wJm.{T@XlU S&)p6iա" |(4wG)?+cXacR/Zu 81C]G.q͏aEč_~ݶb Z-?Ł871%%߿) r@𕃡͐jֆ`EzWǯ6[diG>^PHTF>LUYU.ɢkd5!qr^xiV6i38X4x-R;7"`Ul#CV}Miҧ1 ;raOBORL2r4(MñAK!uJJ|1AleeQ"vh*yLCp(B9Fl\GfI+ Im1_gY;4(/dpJWf# k`U/u/)?YU ojCugX2HX56' _(4ݡ[bl wsZ/8ƴ;)GN䀟mlL5ʅYבؠ,AD'0qzQ(SYZ0Q_Zn_?代f±٢X^jhAYk D cKeCs>]*j}ǖ᯽X$<)ГułzP{?wk6 /øRO[7UY8J]9KK6O_њՂzqt., P±k y>+g؄ڸq ĤzV;DZ@ġgj&Nu-8`|zy^dQ&!?/A89諁cV/>Pтm:lÂehݏ|uRg{{Ro˙g_y$q]!zQmPR FmaMV+,"(9F\^xܐ w>y+efҟ#gj(XBuU-=R5<TsS*:5#JV5np6Bwkz)Y V&< Е SnSN-}扻E+ Z⮟mi^-l0$_. lʸLBKI,"8'C`r{!Ig9ӔQ,憶I,{M`rTh86h}7>EM]Y[ǚ8٨%!NN!cU9"#-۲s3n8@nz9e1У(Yo6u s-{0 ^rTa@9,֪s6fi"6&_a'tHtPt2!_y92 ӑ[B-FUhԴ‰1U s0ND"W A, ȁiSwi֙\*\q".G#Tf۵Nƙgq (M,̔rj/ U7[0`ot</3qF|yXѨd&ӡ0מ2޹T2FMǶz:-Pt 6`1簕/NYB@± s`aOe^M(|2{(3<<bܠyF}OPNFJktg[C7sKT&쮞x= W nn-oCe@+]!;¡7p&ahMIFT9єLeMx CI(m { \ˣ4SdX8NY&GxXÞcIh5vd`4Tz~Zp˱; 3l`^q+2˪Tܗ+,<p1P3OĿDN$"j`x~'1g3&ݝq r! ׭gRwb1k3B4!h>9I7eg>toƽ&WG-NJ\係^&Y"98]A.砂P*c`jd&3FIf *h5l^ .>y&Ѥj~ 32CpNFCM@f3] H s5*Sa"TAZyOy}( eе8:5reh`o-j%~9yǗX`{*K Kw,*Kk@e<溨h|Y@XjJ?-}G$T%FύDŽ Y!QN??׀'ځ^n09w'*2r-'f&(ݓ#S۵^2֧,]ΕAiGq8wDqo$ӹ!GQqhdFm[9yO Tbiגq#6\9)l<v,sЃSlv*jVIRJa^b ZEz0 _AIKMnIݺQ/HrU֏Dz(n4{,&[M\WF6w5 u +G5n kxrDQ*ڦe\)irB$ LXz'Bs%!5Kt[`폰 kIxQwl\j`uW(>ODVb_K̵{tWܠ%iԱ껳i\3OJ,}no&:`eF(ȟ PwQn3vIJz BG:vf'#s QJ3O߱Lj eF!xRxU+|afTЧrXc pyk"VݠkCAQ*S@)LUȃz; v՛vy͇xLMGr 8h'WmcQr]Yv?ֲ(zOkz;Fv|yaY;~4>'ГȖ~2!"$ ((2g ](nNSc.fJ 4V:I7w4=}DzmϷSqX՛#@#{BOhm䁊a &Pmh@CGv-:NuZTgix”<4OX]M U.80t!Vn&]5NL/xz*jqx-~m"$Ez,/_I'nDJ8ؓxBͩىNtXu-=?sr8si.};zAZ4uQα3'*[z<⺯y%Nj#JqqԵBTIWu2 >}r@n^;A|w%* =G4j|0ŝCQaZ%k]zļ79Myt_2XfI-=6سYu/ce3r1v^XÅ{JT<499tp]"Y 2v?_*t`zm(e^7OK<\#OEt@{eD8% !A3싍X]$s=&&#x؆Zr/%,ԋvcs#ĹJ2x%@kRQHA*CDML-;q<ňN!n%񷮍hVOuM06TLHo1<`zu L&0cŪTyNy_!W(qv;o䶀:#ui2mv;ei`O|ltCc\i"#$B\ݵgXh$J⮉3ro! cNBJk¿Kl2Śiobdu|ӒjT]}_ lZ.*4A !<ңp^?ќMB:b:Et(E~-<<2`>G÷իibΝVM%Ǡ1Ǜ(p:׼I/n#4ogImSNMJIff50ed}lakDC$ @~T6XtgJ^-* ődwF8ßqH(F.~wY#^[lG:Bh9F SVMc>6zQxK -n:95&w"0qqqL_*Ld}yj0＊ Qî]iRg2\nƭ͉p]wM5Q䆴c"Sp緺ZHY~LU˪ǔ$\xf]qbHtt ;&gyH14 ulW?i#2Ƥ_OBE"TlL&KT:\Ѭrqצ$?5[wZ%w7YZ$˹\ӮI H&]=a!q}UK*'wu0AOd.%F3)U=<.4AJNJ_;VI7pvJ3rYEky35AD 6 <{w6$200]˲0z_f\@Z+K7Q;Ù5B~xeidn|l6F2Rщ-d9j'fg3Y,'[~^nе'-^NnǁNbyJgzPZm7FHK@k@$Dʥ]k4yU"hhd5AXV)sn x9FQyXJJ\|L*ZVz~XMӊR:$%sy v1[1+D4wt(KʏЧ`pG(~@~w??6h઱frrk*-op~R %oG܃6g'>2B,s&hZž_)twXi8]fmYo[Sݣ`4JWJfY9ݤ~| f%ݭi˅ꆻ͡Լ|-(k^mre0]*OgGcS~9@zdZԛ3}Z.'\ké2}ul"ׇiFk+]KbNF4OqB,{'K+f X*daF[HY*<`s*` B]^؋ u}R>6cO< 0wzqSc s|bΖ3IôcXø'zH{ajESG5 QחL,7`L;c_a6aHp0{ .c`uZ{@OI'³Rǡ `-Civkyt7L] c`hrr=R{u4Jb_ڴמm؊kFoz״ ]@K*fux$@S+0`~1~Βֽ!2QYV* [hO"Z1Vy`WCMޕyUrpŁuƴ2/y "Zb%;ԝLQH_/K:A樌^fc]:j"L>O|jQZ.m+7Ы `$eUz:įO&E3:Q*MhT`۶'d<憙lQ]k9qc1t*Q(Ў]/\bꉦ3VsZ|m1Hm8_8.Y>XMy .կY٦nUDHXϡNs &>,-K-IvE噧qJ:嵸~qdWԒ`9bb'YLdUƊ\D7ȹ*HgƎml|񳦊vڎx S ܁M PڽJ<Ͼ )4]"G_¾Ld&jvNiq{̝Dka6BD,<%dCV_E FJ8 hH<=,1 Ex^g"эj=68R#4 涥-~INGpdm:,h?ė#C@n$)8X`l[-ADBэBG(@M׊pzgV5֥U"ͳvֽu)Jnj8*M<$8 3 -7<.Дu3JrӐ_X{z& ťN0,is uQXvDP*0ddq #?ڧĞPRCAeN v TV_dwĎ TG<5`%=5=n(zȯx];h xrʺf8UX׳pV ׎ל:@p`tRS?a¶籗mxeUFR/wpG1 ]m G4dԵKmn{2KN$̵ZdZjpP m"ljnG)WYƹDmtℹ4F+0_WF}~pc4WGÙFEjԡi) N~(wґ\L[$02 ЍW- 28&9.ڒZe[$+v*|ܪc-p,?td,f>gQ6&.j82I~Pr~m|OJ+N5D%c&n{T &LB@9^U~+2?T(/!C{EBa>WA#m(j2 ~7ML<&/- ֦슠/=knFWxRMN@t.sfӴӏ,}d$(` 2sgEI}1 c.1qDF}6Hd\qO#(HQ:,g2H<P^7v፪]LIAԤʣ`[U2R=b[˜|}(u}Oi7qRF#={khz=`!*RR,N٢*)t+lr,cB;AodFyj]}}3Mh> ֠tz E6 OV'T{BVUĐ% pIj &:0h׆QIiO 5N3eZRbAC}uWS " u:& WiwqP# ŝRiL˄2OJLFVv%Ϊ'&eE*[6_gYl >aIaP8V 8z-^̂ꅒRܐNaR:m\du%G魆$fr7 &C4E YM4]::Σ6W,ghZFh"C ^Ze9 v_ݔZU;ł?@i7En^x?alJ>JF>ƌLZ.Qt<7uSZt1r=XvS6=m`dv l|ŇGȇ/_'!2nMmRps:w"x:(G;GD7 -8iGjpBciqrC/S # z+Y]=9aV<ދ_n8u @: S ngVw y#-vegAlTxJlc)O|\D #g;CuSj>N`fvG0s t² Xen sXB9Q;zYdl;MהSf9RpL'\M=qJCje]s;bXˈg-n=y.J+:;j gi-˅#@%Y=:MbP_O ͢+:-(]ӂZ5{:̅̆ *l*RU!Ȕm /s͗Yn*g[6r-2%Zx!-x/۲#2m ʈ2q2~'Cse)I% 5Se{1Fé:Ҝu'L`ue9gl=ȆSFIC皑* mX)TW`hSl>/'`Ji7k%}ݑd{^f.H9*. q?YP >64,\?뙾uFZ)JRꎣ46EXGs-2_VIE ʲ8aqHd4s?\;!V/J{J4OÙެ<;5N3f$ˁ33h aj \-@Jzǁ% zkI˵) ͌\lHE36,팘"N!,WlxbݍxZːBv 5E8D6 c5:ݾtWE]iipm1SwTru™Ne ' A>\&{J[ۥJ} .Zۯ#C*<hUSs[(2}(SG?FIIX"i&Л jqwuVra[dX0O sUp$gv )s6QP"4=l?"zkkt):)(8.컛uu^ s@3cq~ <_V وf(@"AwH/h#.!0*UNP7a8=G+,Y-,:bnFzPXE 'fS 6+d%$8j+lj%'xOMU-mijHNV(eϋ?ps16Aޜ8"kˎi~iO$^;-tuUXjE8P`c4K#QA)Δ$UWf!Sf,Y-P%tda#M@8 soWGM``.=b)s s0T&^ \#+W@?1=gfxSukOD`!CB=%1ͻVq -=qQ>\ U& S9`\t@Vr~*4.tFXF~ţDΘhX_Vv?ƬXս+.1  =rǬm\ fh4U; BzلI"M\U;ܣ<V" .ηL3JNv͖ G. ܔd_Ytb}F+;2kz%_di0pZ~0Rx #$B6p"#1Ǫ$VEXq 0q*.&rN )?~~b4"hOWMG̹P:|B*rHFHuqݛr&jF" -%{> U$o nԍ%JY Gr2Շ͗dR5 }lm}&iL7X4K`rC>'R ,b6_j,84]Sf3Ls'D!4ylGxgf0{x5 "=UVoI1($*EgïQu&%<L[9:TI&ѼJќ-G+xA >-=TߥEq 𪇘"*!n6u\ NFqHBL0(jjM)VS tuL YzSuTF|! x4kp;fA@ }{Z6Z.u0LlO 4}ب'īN矋~t^Dϟwy{?:xDe?p+dmj2@-ٸW" Q:$ԟL؆t eNF)8)@Fn ]ɂwi/<x 4Nt3Ss"2`{Lzh#k:5 _k_qv1%w1EtIgdOfފc $]^^xnz g{5`L9 JgA`&|bz~S}e~6`^^B4}pCt7 1/DRl iVgߕ3@\ |#oP+"o)\|9{$^@jY/ج*э8N[wQyd;0)`S${`WtOq➒7oĨ52JYۦ޵XqT6. UAΤ638f1~YFnSQ;yL*Vqtޙ )v`ðT_~_yQaC4Ѕ7<)+: &eF"z.ēߺZj7C aP/KgLQ<D/@kP!1މo꫙@-1*0?׍Qi `}ZE"!H)%j Ze:86{sҋA-RRԟ> dkǺ5# cQ/XSJ{lZlÒgH(t;V}Vo0%>ǵHU L VRȏ"멍)j96\U;au6HxFdHVD o7 ,;s(w|D ]wʬU:q܅|=?8]d#Ow33.ce[5bh%a`ҤM$CCkAE2S̓b?ebYѢ%haOTg)[5 ɣnjV&NzN2'e|d-QY 7Z?}ᰄu4]#u)pS7 '"@I,9}t /:YX4^P j.`ʳ®kfr%BM ,*F=,&;0K4ثB yW;ّiǽ~Ux,8` f"SEt֬:im˓C]Z&?U ]ȞVBJ"cՓoV*$xD/G tK$6ȍ:fa8pB{o%:2ښ/,B*<=^O6l˧C+bivɉusZ%;Ҫ9\ҚxG~뉼7EW.r4MgvjCRe^_i3ZE'Gꀿ9LF uH:

М) =ڳ< =zTKb/E~dMy:~s\hyp6U\Н(EܰQ<#,fa2/T*)ȎXfnQ N})꼇*W74H~p0>3l_=Pd^-~v"1GLf”f;},BAG{2 ?/Q .zIAT }* C%:KNYhF.zFVګ3{~^ıF/kpfׅcԥ{FSH%0ns f^̖SdkN;ʻ%TrZ`2 R@VɼnbBC75_e`244ϦӺZ<LպD PyFQOV}i#7K 3_,el3AFn$>E $W#ݗH"Rx,ӒSx.+'ss;lqxxN.' ij m/4dT|Xnʳ k5mO)Gy[m<;cTBPt={EidҫMҢ2;")ivh@#=<v9'5͵˕҉LL(߃ a$t%s/ŚAO_*ͣ3Feu`E,K!|ӏ/bs(e_4 Ol%OlH{DUzXgƦJm}NtA odŦ!~5o[JxZowWy@΄.}?k͇m֟ &,eƁڃ4@yl@[ƲO>Rv uŝ.Mnn9Ԉ$> [Q+†O6xM,6uN4ABG(bSgJƤN#,ϓ>!a9d,'H0=}ZUqI߹EGBb+t'k@\%ہ)[ 4yG r}߀GLs7 y#EomitdQDSw /zyߕ]Gmke۩},S:䃄Jx,9Gj?[[Ti%8-Ub4$ B%$8BH7Vot:&>#|gM2f1 ہ*Do_;[1N}}=kvv <?UsُYcпh_bªY# =Hg JQcÝ0Fo> >*H~mTHDo4^~{??U豋[A>Nפk/Q[dFqqA T'F /S磖$.b!dSK}:hw!uw*XUst\֜>;l8Ѷ:bPW+Akl<0.`9"a:efӝř7$oh< ,u *"6$ֳ+3QGG7_}|H1tҍtJ(֨=O{`CN-Q̆wCO5 [Tpõ7^VeӐ!\5˻1qhLAІ>nK $Jn}F٧t0etY]~AU 1Sv9PK9 'ƙ'sYorZ-j`lQ~0T[8sͦ,QBvQUChRњ4XAl<}i ƪ@3r(b0f9xmz[lT6#gHfMf~:Z(pJs|Oم^bݞ }/᧟}#᧟#H}ϼ bK }=A\" @-mʀqwۺNqZ.tڸ (WX0I3Qg.~u~6Ab FCP1~yV؈Bby,- H;S/Z3m?J\יH_#߼w 6xt|yzX|3ᘝi[+XC0p~jGYꈒ^zϽ,_谻h?[R_v(YciSoծ5ʝIr{  Tx-̀oP-F^dK^ed0c0f|!|(/{r={2g_6IW d%E?pGm:r6" bxyzHf&LVnز[OHehxM"MUdP> 5TJ˭/M5Ǽ8 Iuk봴}gg{^=w:2f8tS[~mfüI-xN2A38ׁi6(J{I֣Mc- !T:ȭNH=Ic@D 1^!pp^[f^60БQuQDufS2P ? +[Zڹ^zfJGqA(tKߙYƫ+_:ZZ )t\t 0>)g_ϑ)/?[& Xd"5YWC:Q؜NZnzG,"ʥѫKSf2%zE:륷!P(M˷0 MyA1!EzB0=2%ozW2.kz(% 9pt&Ų1,"M͓os"˯T=sӖFÕ7y,xZ ~I\XeJz;H-Gm3MSMj4uXrX~]< Ұ*F>$(!L Xesa!gQ [¸1l'a.[ك[M.xAd8w& y,HY˨ud_f$NЫc a9e_$+P.LW c%愘 u}c㸜G 8#}h1FMpԸXU-sWFV:.WVHGo"cA)NU<}R)6PC*/Q9}w<:wk{*O:?t"r6|iNWI$ꁡ ` t"2n4=L<$q#pyMϖSnvTRdtu봩gw/}k[]'hQsO"}h pn y䘶VX_(жlGŖٖz kX `^'#Wsmqnz(06~6IOi*A:aE=I\6jD,;9pr]ؙL' wEjI"jQ-ӟi 5>h4M1E3pc1diBS\lj_/ی8  pqt~A)f@h ǁ\Fz\BVc ,)ɩS>\U[@ -X˫ݥڜՁyghDG8 >Yċ'zEI ʹdBbH?nVJj_t [`=7S\DF[S:LQ ےCvK gѨlEefyaKI B,zte|Hd'M-ugզd\6sv0֏jDt>y:}SYul}΅-tYr"40SW塽PUw n׮k}|ނpK\ | 6r .je4($[sګ_P)m5lӉYYR0ŠB[8"I<CQJCJ耵ha%ͺKhgtlF=ØgTa &\)ܐӍ'X?l].κ\ػMpL$;DcpN]1I9TGG~k>΢uygS1ܝgGļ*,?i7; b,S낊T^FS,yg8e}.eZWv.7Dڑv)5ܽߴ&AAOBaEce0tIX$SЖt]ʧX :hÉ# ƫͩt4z1^uZ_5W&a,lۘD-+k/Fkgy*izmqS |$ao3g+mm"y`S}8b tE֨1ɲ8;u| x^ZfK*# &HUGwE?_$x5'zbc1C{nBݭ H? lP,J ,c_ƻPu[TM,xcK?  C S,eܪ]nuIJ6޴AϧxaɸmdE%}x)& 'EPXZ`ei2Kq1'No )%rQ+YzӼ5z_|}9e"I#:5ey`1>[B~֘&CSB#]MfZO韟gY`ƻ4[g}b%~XV!Kkjb<ՙVJeB+yp{d)z]w]xh&W{w:q&=L'CU?%j-LOŹhc!i6׍x ׈PglJ;~$C^A6ȼ4ÚŅQNNU% ô#{^\+6z 6@;BY)!vd˦zdm/̱cSvdGXJ4}M֥ =He H ad% Ơz7 z-"ٜ߭t}Y8^O9ANb6Þ6P׾Z #+]|:}uA(܇Եor,nG@掭.AR9U!s[AwI#$5C-A:}}l3bP7@Ab9sWL6\ZT-el/v˃u:aߝ&dMnN}Y1߬iNq $Cw 7( A]а߱ZAv4d^% ⟳|KVј&iqf@0AL:G(莏&s0UeПogLsj+byvuo%~PWzmϝrʐT%YSpJ”I/mM}ɦ͡ΌtuZ8 f06g]9*D݇]d1_43>deo 2f '$jCq^e;Jcc "Jǎ5\Soes4,ګ۸FD}p[=}NO0(IRK洚|@m,]u}=V+ f*W *}5w ,ý#'Ǵ. d Q6E:KzJs%Մƥvg_%ȼJ&G8.Fq:ɧ# tf $d& 7n<'u*+J/^X]"605| 4P&8,p,gL&\i~0ow7>?}&wd:<.&"6/fyah{'Eli6tv,`g(CD$Imi ²ۭЙI菜0|p챈Օ_σE~aj)s͜&YVVpY:;:ń &!67hp~7m]%x"%J8~Q j;ͩfȬF/U(gwfuX0?ңO۸D_Fj=(Fx֬$#}-|".ԠuYT4V683~}ȉ^@Wbה99Ujꔻ{^8/c?&:6Y,['aDZK2=1Fk\S: ,ISA UNDo ރXx%I:!.0V'U|Mn&5jos.*Bjiɋ!I -nrɊd E$ƘY H?58/$a(*i`Ӧpvu r>Xe<^tm?|o:PMIt`ZgQzSiM.)U[z#I$'@5(R?8ɓݽ N(h|8l$Pl9(#mݔ>-(+mZ ˀR#DƘgASM=br4MlxEqzw 6pu[u~VV-(n"^6׍_m[<4x+U νk?DMxE1Tze}mw0wP>YAb KGisZ^vU"ݾhy.!QaKJ`8# '&bq\|:qGc0HO]: 7zZ0of2X_{]52%2/'V1Fxzɓ-)ZЍu3"c#3s'-泴,;= Vpz6-Jo ]'^gho<*Z Aq6*vOO2i6>A*LMZsΐVQhL:=]#[dy=Gʧ٦#BWW[[ yAtV1f$Ѯ ݢ8D*kl rߺ/mzMa 7msڝi5.\ԝFHrGRp_}@}T&J?/w+z8̼=3W|U̜ypl"W5²"<dmzJx0 -|-E) pؾIbRKfF0\$Jg+ Gw`“4X ;/ ƧݞY> ƚ(GJd`] 9:fq߰ⲱ}W|:-j R5Bk4*smsU(BN"pMm@ȝEҪ&̵f0VgKuE<ݬ]qe'M7|\ҹ9OΡ/gq=]^E\,9Rr_շo, ۖӑwj]n.[zO=ۢuZPѰHUVՂPu-e:9oAQ1ce2E+?AW \}7]ħ/c5&nHgnPcbDn,uiv787MЛ{WaAWzh|1묛_5ۼ,7C;]Y~ਫ਼uz-hl㤛}= I4 -ڍn֙Im{b|xzՋyy ӻW!x+m?~HWj䨧Y?׺PMvl{_z39"sW7if mh"iߣݰu~ލga4it fio0m| a_ot˶Z؄U7gz/O#L7*<<U,Ӳ_i{;18n>N[qp{^8# <'LC;i @5^w5Cq3XӅQ,`'Oa޳MURUE ᦖzZT)zz3<@ʀ+uQkU1D'8_g:OWmFOUbpXtwN6 xND "i-ﻳjF>] _+v/Cd얃)~/o[F6NԃD_$sq 4T/{ćspz,HAk`[)Xgs|=kV=9b4-OuМ'Y *?'5'?}\M~^~>^^էWP`ӣoGm^4<^OѧOWw^}j|>|?|8=l4@鳛_߿:Fف"d_V#0 /F#ԋ!R`uMF׽tc.9^Lp+X&3n `d{^ݾ4y޼hܾnqCOX_TWfϧ>_gW/ێk¹ۿ{qfΐ8Kܻ]ptLvDd=%hL7 Z9إx ]xcRQ<~ U7j8"KUy Qhwz9u,O[f0eyNz>@1Q/q鍝Ah#/O[xo >́BGs h>aw7RUp|3r ):h^޾rWcuj0d7K^`г=q7w—Ij5vzz?DDyp;T*^|Po>×.n0Ӌdp}mw>\ ^n@&&$pdC9Jvv:JkJN^oZSi1lޟ緯F})-h5gˣ*< [nޟۣgCut,ޢl7@gHTq}q1r_l/Z5_*Ŵl[w[%$قilsQgaYz}U|ܟtEa݄-6SRGԿ>[2Vy3w8T;Ço㛳侉bwspc\|!wԆSu]l7"=?O[`.d>6>}ξ_[׃eOB t<\܁!>?L hݱ3CrL[#Oun8y@oO%@!mM%@;C˻![)-؍5 5h?mmo/a jӰ'H?S?bƛOdvZ "`{|ZSx߾ܢ! |B]S|{5$hy^ma+OGx ]Cp\cy)3(uAD]LZWU )m"= G3?̈is(]890-Ru'E)wj [^)g+DUN!D";Z}uVBVQ%O#XSHGd ,J+c&U<`J)d rBIA0:ZZE<%[1׾1)6~l7Ҥun1rZ^.-v e.3F1,HhzpTο}Ro!B!#@,wp)+[/wMGs]mփޠ"{ϿAvh]zsB6ltAlN_[GLJޛz1G${>oݲ&jESyM,GŁ7ݿQ{p`r¥zAUї7^LQ} M/Öu`E> d~hb`⟥M ѿ ߫աG(Wr>S͏N|Kwo~OW~G yܛ^kIz\Wgei" 0Φy8Pxe!ӿ >r/O%S"ʑkI}0$8U{ί~#y_7H464_o/lUa.Bxhr ,#.`s2"@ ;dpo"tDB̍e[;| og?rF?~p:/"POFq'do_!,Ӌo0f2Hh8dmƓ.b/?_.>&J/#׫!ݥ~+$ #;=dVDQ:wj!XsC|zU^{+}A;L4<&X rnGx ԽQ\m DB(Gp)2B'D` +`Eh2S5@ $ʗBڼ]f`ТcK;t{;@ůؙ<2HZ,1(X~߾ղataP=p_dJ "(waAW5UDJmDKH3 !S(tNnDeKԺts|.Tp޼kK] fzR26AZoTۥ+(P]g!Vh8,T&2H41-;䓫@uJ"(4Y"׋LEVI<+^H˳}}M}:OrQk.e_m1yȋQ0+Zֳ~#PQb_>Wfw;8Z \>L׌cߑvCOA0.MkNwvwp^din`cn3~{@A<<~3/>h";ez;q0dewKVbyЉt1Y4n5.Dۂw1yp^Xm&$~1%#Ge}{;1 >~lL~U bPvTv8q1nƗ1\|K?]]4/goo^qpl?~ǩ{{wݾ}5?xws_}qm0lWۋ yS~sKkS~1/A<9]n_-^Gj_fo/OͷzyvpJMj?&TS=oo_OE Q7bc^<]H?$?o_p\wvm\K5c.I־?2MFw6< }S η׬ݔ.G`?n5>* .M!pؙ^\tnmվm>/6Ҍ>AqTß~9Ylmkᓷo϶7ߖcWϷۇwmlH٧oڬםۑ_zpexN^Ƣqӻw4<~+ F|n>pZ=}y,q}:X^_oη{ip51@tWF|?_2:mޚ{\w||NF|x{7:@䫱_;}?|i>{u|u4ikAGpuy>FtPS_ﷇ?a}g>׼4foFPSeOS?u|x9yuzc}o_mL_<4 ; ozp|ܞl@X_HwyH!=<{QI?ڵ''3~}xvspl;ip׌tW6}k{K|{C\V? ?޾LhponϽ7}!xxp4m^nxr?u^_<_~y}go}l]~noO'߾w1^|~ټ1_߽tϫw7_/QHg?O#BWaL>}v.no?4߿ťw]|pxL_'G|t~239_wY7NRhEyp28h=k|wο؋{ʗ_}u0 OwשQWft^uCӧoo3ř?ߏmt9{Nwξ]: N/7adv+I&<:o\%>ޝݷƇo-A̩i:_| $|}i{_^z}]:TpԇC'so{؎ߙO=ܽ w߃_k\_pniK8͋ӷG/ywq޼zVut޿͎ճwҷ />4GOQ:7^}[BK^4ۻZ|~;R_;/'Io$>ۜ}|z ՗އ%uQ27kO +/>|3^iTJdzAc[w0H>W׃ Qw~0epuvxx~|4ۛw};pZ ˯óai%R)x}R%`E^5lh7?Ķ d/ :`A:W/'=LLg7NdL8)VGn]",얚wfhUvas]_}.y%'}UN5> e^Us0b yPbJ-ׯo/ ڞ}{,ooorT1%y`\hJ`4jx'e5ɯ^$;x&t Xڶp/q8bd3]4yK壜3S]4Dd9]9̜V`8L "wR< .7gJMl}rl?޶\KXowAN.pK&< *o9y;M/,\`ULZ*UB"ޔg}YH\el2G Ɉ53 [7+Px)ࣰ>Ws׋,3Xl&\:ſn{pq&'܈_Q]}b{ >EzZi+??TM*eNSlswAޱ+طw& Lr8P\3ߊȧt2KwQ|y7 {z?~ޛw%g::h@gw)t^=&[~_Ƥ0N~Gһڥ͆H*œ I)tWf{:$X%2+,{A7p{`+/jVm0I&AP8_u?QWIK"KX_zphp{!iSi/66W747}/qCչss$P뵤UsFwUt|RoNN$vojޏDBQGAX1:MMJV1gԠzV, =W?M;j83cT}g5{{%Ff zۉeo٪ zaw(<ɢיOMEm9eò&ivo1)̻ZG2_[5_QKOf0N"Mh(VW^搪 I BwPg'Un4$iII{ 4h5qyN& S/f+Xi#|;eޘ1T{Z gѴ;ȏ^XshG܍aw &C괾{EF]?J#;ƺS68G;n.]QHmdkgY:|o"_^4f*jz4 peo~KoR߿;.|WZ hIҫׯ5 ޝg=vӀQ͝W4qfic {rka*tR-Iu,l-K9evMY{/PuM@yQhT[3y1V}c`iC/ci0H;Ad8zV6 mV@\g#+|R,D,J=+P{o9Dy0)`h J>N ͣ`IvXK&'(e4U۶L4,\?뙾uFZ-,cXM%Ղͼ ˠN{ןf0wC;3S?\ e "ˤ4D>_.@;c8M](H<݄e:eۃ!Ī/8nҚK~sXF(Z~_,kckM«OWwATSƉ $^ڦ$'1n*N6["&ݬOBG.9-:%r횛Buu1ݕ:Жrϭ7 kXLfV6މڮ ^w͞;bX`bހ4 F?eQOrjM95֒3z6]rUXYE2cyK+{̍h؞3>@ף~>,MIV2X9K&v*!{ zͳd[߬gFb#+ e mljL`]@e$؍ߧ_;?|BIqʪ`5w |ɔXW1Ĭz5˫ !v-,dkXc%@q6]̽\o8 7@ '`k/;*u R%/[m$n&ĿC~ݤFWu84PFuT Sʄw?өO2̼6$?='?S^żIW` COP*/IA(G\!Zx(hj!;`M gekaMtd [I Uȟ`q~Ӌ?iTu DE\$r`rkѺTSж\mhDY`)+!¾;/ٺۛm#7lM{U+pp0v68mI2M]#P0ó"`^a&]=pRhj¿KEG;fr ѭ6'h?^S5Wvo`,azBiZzab>!Zw,";ail>u 1T(V "QCPyw!,xاγUiP`7^#nU`vaydK1W!g3""Gs3%|D!&° {dt"R$2?Hg"UhKWQȒ  +kUD)"ĬT P rUWIh=Au o0f"w ȍ0XSZE+*8رrVc9b6UX0X.܍U1t+'Q=0yBCm)R¹Y !Qiy˅sϝ A)sJB0n;0RQTN 0nFeYoleSآ(2oꝺ*jUeO(vVa ,"5ta8^_ \pRY4&z/ YF+d \ l~UA`o DZu]-Hߵrjv& 񴓢ЁQH,bo CD{"*C⧜NaW)N;[+jUK]32W);JMMAk,%W( IS~\!}h6Wn.axpXyܥ*2stt0X`f ayq3Kw*:cGN德JtyQp A8lt ke*X x;3^Nݣ؍c+RPMxm j♱4%-\F-nNԱrjO.*&ln2!PnߝFÁtfgޠ~='zDAF;4ǹTNMM"HEN '.Z'i `x&*=n6e8ȁMR ,-8l=u?pׅn؂4[+c9D&Ghj:6qF])/a쫇WXT K]8]̜`k 0Ǜ3ò63vp& QVeZ0 p"ڵM,R.tu.6y섮д R] 7ҹogx~vj4r5懗AܙRviu\aQ%Nk( Lƻ5_[ơ=G'T1yB.?'AuI3gcm|j˩NL%#U4*5)oSZNuJ+\/p GOVc, }z oI\dMGj:K@-.bhNt#m:kl5Ks2[.N/ljfLQ4ռK.4 r"nՑyV(Q3b.Z ׁ\(3Xӧf!zBQg)RL67.2v7"1ji`uzq{8~x#-xf2j㷲?#\1?dyj ,7׃F<0܌l^#, -@43E 0] }UxMm&Rs؈'?Xۼ+Xm{p r7wxE^-̷jw=enbtMМC4ᖉn(jt:|͉<{z!jfy'ꆃ -uo{'(S~e+* -Yvys{(fkc4f/eg 3ڵ*h-%?/;7\(HOSgN WPzI("n6 tRUߵh0;ݾmcS;?.UPL) 1uu'TFUj!5^onu9ݮK9ϖxE-Sč „{ M-rk D,7==  uQB_ϝBD` Sx^ט}|މv; (pWK<\X<$,e]jZVo6&`ywd^yd7bz-MZT#JQʁUvO}P`GYgMz.P-㞙jY긾*4'ذ;0Fnͷ_84QGz6F7P&]=oƮh4̣}yBU+WfU#,{Coڛ~W-o ]g⡐KƖFGsun0L ޮt*7'u%|+!oagjDR!ȳS3*iFU +o[qATgHEM+N (Cr*](Nf51O OSY)F{?  y^$^{Ya6_FH_ n}K3 +Q,U,;C–JKo%yL$|p}#4}0LVX )&YGeGIch2D \8" ZҊ ,5@%)7W-{E>h n`ě&ҲzhtVXlCjݙ5 M69muvģ/¼%0C*KocOF^VCOez"D$1?;`6v6ęfޝXzS7ڵ\׍돬Qv”8Rt&\DH`H ?ͩ8]A:sG &QK}O6TRrKµbaLh/$U=IRZU ΢TI"vh%`R&wʑ BjGbGk]aIIJJuIB47ȼ*|sy$Up^dN UE&賅K{Gb4‘w5`- -: yB+Z`Pfol3O MGfI!6#dqzWGx?t]uxn92ף!!$3IJ1? ㈓|FHYCQO&Ap(c?fؐ h?&!%2JFE47a b曟iW^CS -~釹 s; T&9wn6Mo&)ȴ67gz\NԵBdFl`>ll :vr #u *$}xqGd#uA8dA-bH+î,:4BOGN!ORh7u? >}N04v0:.1t:#G/D$6gSoF )1_9nԡw0mA!+8ƦaUu.[h8+&v\NA|urK2J+K)zd4[2oTtCa/(@x~g/@mnHV C7&k4qM1 ۝.{6v`؟ᴀ{Ù6Qr T!3³ʵ$`O #R3*OPe1p͖B[- :|-wHbiR$=N@̓LH[.\^Qمۭ^p{,FVWM!%TgJ׻Yv|q|TUz!z `Ub8N@D!a bGQ&A=bHiP&]GX=hpnFԫ[QT ᗩz񕮥fj'~*,f>_39JEK^U@A^6߳'*&n'AaN{D[ bGei,ҔUog_ hH >N++Ƃ_㪫Jeܙ)r433dЍO*)iAOIA2QNqWf M_Iݑ@}Hd) \6HLOiIxi L7$G:`imVpƃsƋ-q*4=A Tl24~< +8lTߪ=$prz9'au4mF:sC6Ul3V}H${khVk(CMNܬys4(+jK  QBSs; ķroѠ7Ri7+jnԩ(hNo@8тRB74{$RP]HYyO`l@vlHFǘ g`,%JsR&, +{%Tf jDPRϥ%DvMT,o Ng@A< -qP?dfd.!囝+T'Tfp˥6|W\Ffro)ӆSB97*;fiBsr-p], RBRPȠUoP!8m" 0U,] oί7C C)rN3v5HuJS׻AE>xJuE) +=Y!CXJƹBd]@ &i VQQ 0KM3J<3 )[OD/ J?7W8e􈊆xQE̍+,=:u] :˩Ab-(|ebaGeё%GZ7aDpϒ{ ʘM.D5D27LoLF"<ԋ̤Y8s־b$?ߦ ](UFn$#W'42|e h4P"wŃOUT~a>*1ExxaCk39jUedETSj8/$"o=5AU+V|RJL-F _dPz^\--hn$|" L%'Ъz@R&W{/_Hغ wf<ޢ`„Ap̓w{۫ bio]694§/XBVEpId0:VsgG|S6$t(;U GwI tNTKoh,A1i|̵[aS/-ӄG)4bWD$͑B'n=kË9 /!܉[y/ Z.-W1&:b@/rqZ|\pGȚ鞀lܡp>| L\M-9K.-Ex7]W˱v070؛(dmjܕVFG1ej6Gulo( {TIb^ sMSF 59\st[+1{)َ'[el׀3tz:Bea!$ #d t|}*Bǀ%9"{{57ڸQtRY3tۻ; " v9WJXHGs[p~X2nBv=뵸IT?'DZ+Key,T(L۶c O [pP} U,D*b첥e# Q9bu"1TJxYĈQYD-hbq;1Yԋ\fr,RzsIOI/#"Z4t,u5b:Kg+1ʉsg64cbREAyRb@ϮM- kiGdy;(2-.3 )MVmɵybD GfKxS5|pbeƏ$¸q.4 |a*_/Khw_]WLNRRPQZ3-kI]>%?잔[T{~DY]JK%l--Ko-;ipAGNdz;CYدjÒ'nط'"kSYd#] S7wn /]?nЗH ^i,_ѐh[_ZEFNtG]0RԡUYFacnArO Q,,a\s5Ur7Q^2tY̜M=U:*( < %z:Q %N kcs=y{a3*'6A{!,E4yo6`މa {{cWo%̝XN5Kuv'EfYs(p:Qެm1M*._vebztbIط˕ ( i>#_?]aTyQDHd?p0G3\M#f4a8s(]d`Zn+v3E2q@]))t`"w "aߥz +N^D/DL6J)J۳OId8sƙ5hp:feRuc$Yg% B,7Iu.' m`_hcpS;icEHÃS.:vXGr>ˌMGF0k``]c5`򝾞x6 kܕ={DGXkf訴Vvę &,*vmi8]q!{]u :Y;Wþ3A AXGob&go{{{TJ0qTpZ5FM`ԈȈwcϭ(`ZƅmIAMCwW|3h݄wJm.{T@XlU S&)p6iա" |(4wG)?+cXacR/Zu 81C]G.q͏aEč_~ݶb Z-?Ł871%%߿) r@𕃡͐jֆ`EzWǯ6[diG>^PHTF>LUYU.ɢkd5!qr^xiV6i38X4x-R;7"`Ul#CV}Miҧ1 ;raOBORL2r4(MñAK!uJJ|1AleeQ"vh*yLCp(B9Fl\GfI+ Im1_gY;4(/dpJWf# k`U/u/)?YU ojCugX2HX56' _(4ݡ[bl wsZ/8ƴ;)GN䀟mlL5ʅYבؠ,AD'0qzQ(SYZ0Q_Zn_?代f±٢X^jhAYk D cKeCs>]*j}ǖ᯽X$<)ГułzP{?wk6 /øRO[7UY8J]9KK6O_њՂzqt., P±k y>+g؄ڸq ĤzV;DZ@ġgj&Nu-8`|zy^dQ&!?/A89諁cV/>Pтm:lÂehݏ|uRg{{Ro˙g_y$q]!zQmPR FmaMV+,"(9F\^xܐ w>y+efҟ#gj(XBuU-=R5<TsS*:5#JV5np6Bwkz)Y V&< Е SnSN-}扻E+ Z⮟mi^-l0$_. lʸLBKI,"8'C`r{!Ig9ӔQ,憶I,{M`rTh86h}7>EM]Y[ǚ8٨%!NN!cU9"#-۲s3n8@nz9e1У(Yo6u s-{0 ^rTa@9,֪s6fi"6&_a'tHtPt2!_y92 ӑ[B-FUhԴ‰1U s0ND"W A, ȁiSwi֙\*\q".G#Tf۵Nƙgq (M,̔rj/ U7[0`ot</3qF|yXѨd&ӡ0מ2޹T2FMǶz:-Pt 6`1簕/NYB@± s`aOe^M(|2{(3<<bܠyF}OPNFJktg[C7sKT&쮞x= W nn-oCe@+]!;¡7p&ahMIFT9єLeMx CI(m { \ˣ4SdX8NY&GxXÞcIh5vd`4Tz~Zp˱; 3l`^q+2˪Tܗ+,<p1P3OĿDN$"j`x~'1g3&ݝq r! ׭gRwb1k3B4!h>9I7eg>toƽ&WG-NJ\係^&Y"98]A.砂P*c`jd&3FIf *h5l^ .>y&Ѥj~ 32CpNFCM@f3] H s5*Sa"TAZyOy}( eе8:5reh`o-j%~9yǗX`{*K Kw,*Kk@e<溨h|Y@XjJ?-}G$T%FύDŽ Y!QN??׀'ځ^n09w'*2r-'f&(ݓ#S۵^2֧,]ΕAiGq8wDqo$ӹ!GQqhdFm[9yO Tbiגq#6\9)l<v,sЃSlv*jVIRJa^b ZEz0 _AIKMnIݺQ/HrU֏Dz(n4{,&[M\WF6w5 u +G5n kxrDQ*ڦe\)irB$ LXz'Bs%!5Kt[`폰 kIxQwl\j`uW(>ODVb_K̵{tWܠ%iԱ껳i\3OJ,}no&:`eF(ȟ PwQn3vIJz BG:vf'#s QJ3O߱Lj eF!xRxU+|afTЧrXc pyk"VݠkCAQ*S@)LUȃz; v՛vy͇xLMGr 8h'WmcQr]Yv?ֲ(zOkz;Fv|yaY;~4>'ГȖ~2!"$ ((2g ](nNSc.fJ 4V:I7w4=}DzmϷSqX՛#@#{BOhm䁊a &Pmh@CGv-:NuZTgix”<4OX]M U.80t!Vn&]5NL/xz*jqx-~m"$Ez,/_I'nDJ8ؓxBͩىNtXu-=?sr8si.};zAZ4uQα3'*[z<⺯y%Nj#JqqԵBTIWu2 >}r@n^;A|w%* =G4j|0ŝCQaZ%k]zļ79Myt_2XfI-=6سYu/ce3r1v^XÅ{JT<499tp]"Y 2v?_*t`zm(e^7OK<\#OEt@{eD8% !A3싍X]$s=&&#x؆Zr/%,ԋvcs#ĹJ2x%@kRQHA*CDML-;q<ňN!n%񷮍hVOuM06TLHo1<`zu L&0cŪTyNy_!W(qv;o䶀:#ui2mv;ei`O|ltCc\i"#$B\ݵgXh$J⮉3ro! cNBJk¿Kl2Śiobdu|ӒjT]}_ lZ.*4A !<ңp^?ќMB:b:Et(E~-<<2`>G÷իibΝVM%Ǡ1Ǜ(p:׼I/n#4ogImSNMJIff50ed}lakDC$ @~T6XtgJ^-* ődwF8ßqH(F.~wY#^[lG:Bh9F SVMc>6zQxK -n:95&w"0qqqL_*Ld}yj0＊ Qî]iRg2\nƭ͉p]wM5Q䆴c"Sp緺ZHY~LU˪ǔ$\xf]qbHtt ;&gyH14 ulW?i#2Ƥ_OBE"TlL&KT:\Ѭrqצ$?5[wZ%w7YZ$˹\ӮI H&]=a!q}UK*'wu0AOd.%F3)U=<.4AJNJ_;VI7pvJ3rYEky35AD 6 <{w6$200]˲0z_f\@Z+K7Q;Ù5B~xeidn|l6F2Rщ-d9j'fg3Y,'[~^nе'-^NnǁNbyJgzPZm7FHK@k@$Dʥ]k4yU"hhd5AXV)sn x9FQyXJJ\|L*ZVz~XMӊR:$%sy v1[1+D4wt(KʏЧ`pG(~@~w??6h઱frrk*-op~R %oG܃6g'>2B,s&hZž_)twXi8]fmYo[Sݣ`4JWJfY9ݤ~| f%ݭi˅ꆻ͡Լ|-(k^mre0]*OgGcS~9@zdZԛ3}Z.'\ké2}ul"ׇiFk+]KbNF4OqB,{'K+f X*daF[HY*<`s*` B]^؋ u}R>6cO< 0wzqSc s|bΖ3IôcXø'zH{ajESG5 QחL,7`L;c_a6aHp0{ .c`uZ{@OI'³Rǡ `-Civkyt7L] c`hrr=R{u4Jb_ڴמm؊kFoz״ ]@K*fux$@S+0`~1~Βֽ!2QYV* [hO"Z1Vy`WCMޕyUrpŁuƴ2/y "Zb%;ԝLQH_/K:A樌^fc]:j"L>O|jQZ.m+7Ы `$eUz:įO&E3:Q*MhT`۶'d<憙lQ]k9qc1t*Q(Ў]/\bꉦ3VsZ|m1Hm8_8.Y>XMy .կY٦nUDHXϡNs &>,-K-IvE噧qJ:嵸~qdWԒ`9bb'YLdUƊ\D7ȹ*HgƎml|񳦊vڎx S ܁M PڽJ<Ͼ )4]"G_¾Ld&jvNiq{̝Dka6BD,<%dCV_E FJ8 hH<=,1 Ex^g"эj=68R#4 涥-~INGpdm:,h?ė#C@n$)8X`l[-ADBэBG(@M׊pzgV5֥U"ͳvֽu)Jnj8*M<$8 3 -7<.Дu3JrӐ_X{z& ťN0,is uQXvDP*0ddq #?ڧĞPRCAeN v TV_dwĎ TG<5`%=5=n(zȯx];h xrʺf8UX׳pV ׎ל:@p`tRS?a¶籗mxeUFR/wpG1 ]m G4dԵKmn{2KN$̵ZdZjpP m"ljnG)WYƹDmtℹ4F+0_WF}~pc4WGÙFEjԡi) N~(wґ\L[$02 ЍW- 28&9.ڒZe[$+v*|ܪc-p,?td,f>gQ6&.j82I~Pr~m|OJ+N5D%c&n{T &LB@9^U~+2?T(/!C{EBa>WA#m(j2 ~7ML<&/- ֦슠/=knFWxRMN@t.sfӴӏ,}d$(` 2sgEI}1 c.1qDF}6Hd\qO#(HQ:,g2H<P^7v፪]LIAԤʣ`[U2R=b[˜|}(u}Oi7qRF#={khz=`!*RR,N٢*)t+lr,cB;AodFyj]}}3Mh> ֠tz E6 OV'T{BVUĐ% pIj &:0h׆QIiO 5N3eZRbAC}uWS " u:& WiwqP# ŝRiL˄2OJLFVv%Ϊ'&eE*[6_gYl >aIaP8V 8z-^̂ꅒRܐNaR:m\du%G魆$fr7 &C4E YM4]::Σ6W,ghZFh"C ^Ze9 v_ݔZU;ł?@i7En^x?alJ>JF>ƌLZ.Qt<7uSZt1r=XvS6=m`dv l|ŇGȇ/_'!2nMmRps:w"x:(G;GD7 -8iGjpBciqrC/S # z+Y]=9aV<ދ_n8u @: S ngVw y#-vegAlTxJlc)O|\D #g;CuSj>N`fvG0s t² Xen sXB9Q;zYdl;MהSf9RpL'\M=qJCje]s;bXˈg-n=y.J+:;j gi-˅#@%Y=:MbP_O ͢+:-(]ӂZ5{:̅̆ *l*RU!Ȕm /s͗Yn*g[6r-2%Zx!-x/۲#2m ʈ2q2~'Cse)I% 5Se{1Fé:Ҝu'L`ue9gl=ȆSFIC皑* mX)TW`hSl>/'`Ji7k%}ݑd{^f.H9*. q?YP >64,\?뙾uFZ)JRꎣ46EXGs-2_VIE ʲ8aqHd4s?\;!V/J{J4OÙެ<;5N3f$ˁ33h aj \-@Jzǁ% zkI˵) ͌\lHE36,팘"N!,WlxbݍxZːBv 5E8D6 c5:ݾtWE]iipm1SwTru™Ne ' A>\&{J[ۥJ} .Zۯ#C*<hUSs[(2}(SG?FIIX"i&Л jqwuVra[dX0O sUp$gv )s6QP"4=l?"zkkt):)(8.컛uu^ s@3cq~ <_V وf(@"AwH/h#.!0*UNP7a8=G+,Y-,:bnFzPXE 'fS 6+d%$8j+lj%'xOMU-mijHNV(eϋ?ps16Aޜ8"kˎi~iO$^;-tuUXjE8P`c4K#QA)Δ$UWf!Sf,Y-P%tda#M@8 soWGM``.=b)s s0T&^ \#+W@?1=gfxSukOD`!CB=%1ͻVq -=qQ>\ U& S9`\t@Vr~*4.tFXF~ţDΘhX_Vv?ƬXս+.1  =rǬm\ fh4U; BzلI"M\U;ܣ<V" .ηL3JNv͖ G. ܔd_Ytb}F+;2kz%_di0pZ~0Rx #$B6p"#1Ǫ$VEXq 0q*.&rN )?~~b4"hOWMG̹P:|B*rHFHuqݛr&jF" -%{> U$o nԍ%JY Gr2Շ͗dR5 }lm}&iL7X4K`rC>'R ,b6_j,84]Sf3Ls'D!4ylGxgf0{x5 "=UVoI1($*EgïQu&%<L[9:TI&ѼJќ-G+xA >-=TߥEq 𪇘"*!n6u\ NFqHBL0(jjM)VS tuL YzSuTF|! x4kp;fA@ }{Z6Z.u0LlO 4}ب'īN矋~t^Dϟwy{?:xDe?p+dmj2@-ٸW" Q:$ԟL؆t eNF)8)@Fn ]ɂwi/<x 4Nt3Ss"2`{Lzh#k:5 _k_qv1%w1EtIgdOfފc $]^^xnz g{5`L9 JgA`&|bz~S}e~6`^^B4}pCt7 1/DRl iVgߕ3@\ |#oP+"o)\|9{$^@jY/ج*э8N[wQyd;0)`S${`WtOq➒7oĨ52JYۦ޵XqT6. UAΤ638f1~YFnSQ;yL*Vqtޙ )v`ðT_~_yQaC4Ѕ7<)+: &eF"z.ēߺZj7C aP/KgLQ<D/@kP!1މo꫙@-1*0?׍Qi `}ZE"!H)%j Ze:86{sҋA-RRԟ> dkǺ5# cQ/XSJ{lZlÒgH(t;V}Vo0%>ǵHU L VRȏ"멍)j96\U;au6HxFdHVD o7 ,;s(w|D ]wʬU:q܅|=?8]d#Ow33.ce[5bh%a`ҤM$CCkAE2S̓b?ebYѢ%haOTg)[5 ɣnjV&NzN2'e|d-QY 7Z?}ᰄu4]#u)pS7 '"@I,9}t /:YX4^P j.`ʳ®kfr%BM ,*F=,&;0K4ثB yW;ّiǽ~Ux,8` f"SEt֬:im˓C]Z&?U ]ȞVBJ"cՓoV*$xD/G tK$6ȍ:fa8pB{o%:2ښ/,B*<=^O6l˧C+bivɉusZ%;Ҫ9\ҚxG~뉼7EW.r4MgvjCRe^_i3ZE'Gꀿ9LF uH:

М) =ڳ< =zTKb/E~dMy:~s\hyp6U\Н(EܰQ<#,fa2/T*)ȎXfnQ N})꼇*W74H~p0>3l_=Pd^-~v"1GLf”f;},BAG{2 ?/Q .zIAT }* C%:KNYhF.zFVګ3{~^ıF/kpfׅcԥ{FSH%0ns f^̖SdkN;ʻ%TrZ`2 R@VɼnbBC75_e`244ϦӺZ<LպD PyFQOV}i#7K 3_,el3AFn$>E $W#ݗH"Rx,ӒSx.+'ss;lqxxN.' ij m/4dT|Xnʳ k5mO)Gy[m<;cTBPt={EidҫMҢ2;")ivh@#=<v9'5͵˕҉LL(߃ a$t%s/ŚAO_*ͣ3Feu`E,K!|ӏ/bs(e_4 Ol%OlH{DUzXgƦJm}NtA odŦ!~5o[JxZowWy@΄.}?k͇m֟ &,eƁڃ4@yl@[ƲO>Rv uŝ.Mnn9Ԉ$> [Q+†O6xM,6uN4ABG(bSgJƤN#,ϓ>!a9d,'H0=}ZUqI߹EGBb+t'k@\%ہ)[ 4yG r}߀GLs7 y#EomitdQDSw /zyߕ]Gmke۩},S:䃄Jx,9Gj?[[Ti%8-Ub4$ B%$8BH7Vot:&>#|gM2f1 ہ*Do_;[1N}}=kvv <?UsُYcпh_bªY# =Hg JQcÝ0Fo> >*H~mTHDo4^~{??U豋[A>Nפk/Q[dFqqA T'F /S磖$.b!dSK}:hw!uw*XUst\֜>;l8Ѷ:bPW+Akl<0.`9"a:efӝř7$oh< ,u *"6$ֳ+3QGG7_}|H1tҍtJ(֨=O{`CN-Q̆wCO5 [Tpõ7^VeӐ!\5˻1qhLAІ>nK $Jn}F٧t0etY]~AU 1Sv9PK9 'ƙ'sYorZ-j`lQ~0T[8sͦ,QBvQUChRњ4XAl<}i ƪ@3r(b0f9xmz[lT6#gHfMf~:Z(pJs|Oم^bݞ }/᧟}#᧟#H}ϼ bK }=A\" @-mʀqwۺNqZ.tڸ (WX0I3Qg.~u~6Ab FCP1~yV؈Bby,- H;S/Z3m?J\יH_#߼w 6xt|yzX|3ᘝi[+XC0p~jGYꈒ^zϽ,_谻h?[R_v(YciSoծ5ʝIr{  Tx-̀oP-F^dK^ed0c0f|!|(/{r={2g_6IW d%E?pGm:r6" bxyzHf&LVnز[OHehxM"MUdP> 5TJ˭/M5Ǽ8 Iuk봴}gg{^=w:2f8tS[~mfüI-xN2A38ׁi6(J{I֣Mc- !T:ȭNH=Ic@D 1^!pp^[f^60БQuQDufS2P ? +[Zڹ^zfJGqA(tKߙYƫ+_:ZZ )t\t 0>)g_ϑ)/?[& Xd"5YWC:Q؜NZnzG,"ʥѫKSf2%zE:륷!P(M˷0 MyA1!EzB0=2%ozW2.kz(% 9pt&Ų1,"M͓os"˯T=sӖFÕ7y,xZ ~I\XeJz;H-Gm3MSMj4uXrX~]< Ұ*F>$(!L Xesa!gQ [¸1l'a.[ك[M.xAd8w& y,HY˨ud_f$NЫc a9e_$+P.LW c%愘 u}c㸜G 8#}h1FMpԸXU-sWFV:.WVHGo"cA)NU<}R)6PC*/Q9}w<:wk{*O:?t"r6|iNWI$ꁡ ` t"2n4=L<$q#pyMϖSnvTRdtu봩gw/}k[]'hQsO"}h pn y䘶VX_(жlGŖٖz kX `^'#Wsmqnz(06~6IOi*A:aE=I\6jD,;9pr]ؙL' wEjI"jQ-ӟi 5>h4M1E3pc1diBS\lj_/ی8  pqt~A)f@h ǁ\Fz\BVc ,)ɩS>\U[@ -X˫ݥڜՁyghDG8 >Yċ'zEI ʹdBbH?nVJj_t [`=7S\DF[S:LQ ےCvK gѨlEefyaKI B,zte|Hd'M-ugզd\6sv0֏jDt>y:}SYul}΅-tYr"40SW塽PUw n׮k}|ނpK\ | 6r .je4($[sګ_P)m5lӉYYR0ŠB[8"I<CQJCJ耵ha%ͺKhgtlF=ØgTa &\)ܐӍ'X?l].κ\ػMpL$;DcpN]1I9TGG~k>΢uygS1ܝgGļ*,?i7; b,S낊T^FS,yg8e}.eZWv.7Dڑv)5ܽߴ&AAOBaEce0tIX$SЖt]ʧX :hÉ# ƫͩt4z1^uZ_5W&a,lۘD-+k/Fkgy*izmqS |$ao3g+mm"y`S}8b tE֨1ɲ8;u| x^ZfK*# &HUGwE?_$x5'zbc1C{nBݭ H? lP,J ,c_ƻPu[TM,xcK?  C S,eܪ]nuIJ6޴AϧxaɸmdE%}x)& 'EPXZ`ei2Kq1'No )%rQ+YzӼ5z_|}9e"I#:5ey`1>[B~֘&CSB#]MfZO韟gY`ƻ4[g}b%~XV!Kkjb<ՙVJeB+yp{d)z]w]xh&W{w:q&=L'CU?%j-LOŹhc!i6׍x ׈PglJ;~$C^A6ȼ4ÚŅQNNU% ô#{^\+6z 6@;BY)!vd˦zdm/̱cSvdGXJ4}M֥ =He H ad% Ơz7 z-"ٜ߭t}Y8^O9ANb6Þ6P׾Z #+]|:}uA(܇Եor,nG@掭.AR9U!s[AwI#$5C-A:}}l3bP7@Ab9sWL6\ZT-el/v˃u:aߝ&dMnN}Y1߬iNq $Cw 7( A]а߱ZAv4d^% ⟳|KVј&iqf@0AL:G(莏&s0UeПogLsj+byvuo%~PWzmϝrʐT%YSpJ”I/mM}ɦ͡ΌtuZ8 f06g]9*D݇]d1_43>deo 2f '$jCq^e;Jcc "Jǎ5\Soes4,ګ۸FD}p[=}NO0(IRK洚|@m,]u}=V+ f*W *}5w ,ý#'Ǵ. d Q6E:KzJs%Մƥvg_%ȼJ&G8.Fq:ɧ# tf $d& 7n<'u*+J/^X]"605| 4P&8,p,gL&\i~0ow7>?}&wd:<.&"6/fyah{'Eli6tv,`g(CD$Imi ²ۭЙI菜0|p챈Օ_σE~aj)s͜&YVVpY:;:ń &!67hp~7m]%x"%J8~Q j;ͩfȬF/U(gwfuX0?ңO۸D_Fj=(Fx֬$#}-|".ԠuYT4V683~}ȉ^@Wbה99Ujꔻ{^8/c?&:6Y,['aDZK2=1Fk\S: ,ISA UNDo ރXx%I:!.0V'U|Mn&5jos.*Bjiɋ!I -nrɊd E$ƘY H?58/$a(*i`Ӧpvu r>Xe<^tm?|o:PMIt`ZgQzSiM.)U[z#I$'@5(R?8ɓݽ N(h|8l$Pl9(#mݔ>-(+mZ ˀR#DƘgASM=br4MlxEqzw 6pu[u~VV-(n"^6׍_m[<4x+U νk?DMxE1Tze}mw0wP>YAb KGisZ^vU"ݾhy.!QaKJ`8# '&bq\|:qGc0HO]: 7zZ0of2X_{]52%2/'V1Fxzɓ-)ZЍu3"c#3s'-泴,;= Vpz6-Jo ]'^gho<*Z Aq6*vOO2i6>A*LMZsΐVQhL:=]#[dy=Gʧ٦#BWW[[ yAtV1f$Ѯ ݢ8D*kl rߺ/mzMa 7msڝi5.\ԝFHrGRp_}@}T&J?/w+z8̼=3W|U̜ypl"W5²"<dmzJx0 -|-E) pؾIbRKfF0\$Jg+ Gw`“4X ;/ ƧݞY> ƚ(GJd`] 9:fq߰ⲱ}W|:-j R5Bk4*smsU(BN"pMm@ȝEҪ&̵f0VgKuE<ݬ]qe'M7|\ҹ9OΡ/gq=]^E\,9Rr_շo, ۖӑwj]n.[zO=ۢuZPѰHUVՂPu-e:9oAQ1c Pharmacovigilance – Cliniversity

Explore courses
Book a Demo

What is Pharmacovigilance?

Pharmacovigilance (PV) is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. It plays a crucial role in ensuring the safety and efficacy of medicines. Pharmacovigilance professionals monitor and evaluate the side effects of medications, aiming to improve patient safety and overall public health by minimizing the risks associated with pharmaceutical products.

Enquire now

Career Opportunities in Pharmacovigilance

A career in pharmacovigilance offers a range of opportunities across the pharmaceutical and healthcare sectors. Here are some of the roles you can explore:

Drug Safety Associate:

Involves monitoring and reporting adverse drug reactions.

Pharmacovigilance Scientist:

Conducts in-depth analysis of drug safety data.

Regulatory Affairs Specialist:

Ensures compliance with pharmacovigilance regulations.

Clinical Research Associate:

Monitors clinical trials and ensures safety reporting.

Medical Reviewer:

Reviews safety data and prepares regulatory submission documents.

Risk Management Specialist:

Develops risk management plans and strategies.

Pharmacovigilance Manager:

Oversees PV operations and teams, ensuring adherence to regulations and best practices.

Quality Assurance Specialist:

Ensures the quality and compliance of pharmacovigilance processes.

Career Growth in Pharmacovigilance

Pharmacovigilance offers significant potential for career growth and advancement. Here’s a typical career progression in the field:

  • Entry-Level Roles
    Start as a drug safety associate or clinical research associate to gain foundational experience.
  • Advanced Certifications:
    Obtain certifications such as Certified Pharmacovigilance Professional (CPP) to enhance your credentials..
  • Specialization
    Focus on specific areas like signal detection, risk management, or regulatory affairs.
  • Leadership Roles
    Move into supervisory or managerial positions, overseeing teams and pharmacovigilance activities.
  • Consulting and Advisory Roles
    Become a consultant or advisor, providing expert guidance on drug safety and regulatory compliance.
  • Executive Positions
    Transition into high-level roles such as Director or Vice President of Pharmacovigilance, shaping the strategic direction of PV activities.

Why Pursue a Career in Pharmacovigilance?

High Demand:

The increasing complexity of drug development and stringent regulatory requirements drive the demand for skilled pharmacovigilance professionals.

Competitive Salaries:

Pharmacovigilance roles offer attractive salaries, with potential for higher earnings as you gain experience and certifications.

Global Opportunities:

PV professionals are needed worldwide, offering opportunities for international careers.

Continuous Learning:

The dynamic nature of pharmacovigilance ensures ongoing learning and professional development.

Impactful Work:

Your work directly contributes to patient safety and public health, making a significant difference in the healthcare landscape.

Join the Pharmacovigilance Profession

A career in pharmacovigilance is more than just a job—it’s a pathway to a rewarding and impactful role in healthcare. With numerous opportunities for growth, competitive salaries, and the chance to make a difference, pharmacovigilance is an excellent career choice for those passionate about drug safety and public health.
Ring at : +91 7066457703

Join Us

Here Is The Most Frequently
Asked Questions

What is pharmacovigilance?

Pharmacovigilance (PV) is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. It aims to ensure the safety and efficacy of medicines by monitoring and evaluating their side effects and taking necessary actions to minimize risks and enhance patient care.

Pharmacovigilance is crucial because it helps:

Ensure the safety and efficacy of medications.
Detect and evaluate adverse drug reactions (ADRs).
Prevent harm to patients by minimizing risks associated with drug use.
Provide essential data for regulatory actions and decision-making.
Improve public health and trust in the healthcare system.

An Adverse Event (AE) is any undesirable experience associated with the use of a medical product in a patient, which does not necessarily have a causal relationship with the product. An Adverse Drug Reaction (ADR), on the other hand, is a harmful and unintended response to a medicinal product that occurs at normal doses used for prophylaxis, diagnosis, or therapy. ADRs imply a causal relationship between the drug and the adverse effect.

The key responsibilities of a pharmacovigilance professional include:

  • Collecting, processing, and evaluating reports of adverse drug reactions.
  • Conducting signal detection and risk assessment.
  • Preparing and submitting safety reports to regulatory authorities.
  • Developing risk management plans and strategies.
  • Ensuring compliance with regulatory requirements and guidelines.
  • Collaborating with healthcare professionals to improve drug safety.
  • Conducting post-marketing surveillance and clinical trial safety monitoring.

A Periodic Safety Update Report (PSUR) is a pharmacovigilance document required by regulatory authorities to provide an update on the safety profile of a marketed drug. PSURs summarize the adverse effects, efficacy data, and safety signals observed during a specified period. They include an analysis of the benefit-risk balance of the drug and any necessary actions to mitigate risks.

When detecting a new safety signal:

  • I thoroughly review and analyze the data to confirm the signal.
  • I assess the potential impact on patient safety.
  • I notify relevant stakeholders, including regulatory authorities and healthcare providers.
  • I conduct a detailed investigation to understand the nature and cause of the signal.
  • I develop and implement risk mitigation strategies, such as updating product labeling or conducting additional studies.

I continuously monitor the signal and its impact on the benefit-risk balance of the drug.

In a previous role, I identified an increase in reports of severe skin reactions associated with a newly marketed drug. I conducted a detailed analysis and confirmed a safety signal. I collaborated with the clinical and regulatory teams to assess the risk, and we updated the product labeling to include a warning about the potential for severe skin reactions. Additionally, we communicated with healthcare providers to ensure they were aware of the new safety information and monitored the situation closely to ensure the risk was managed effectively.

Signal detection in pharmacovigilance is the process of identifying and evaluating new information on potential adverse effects of drugs that may not have been previously recognized. It is important because it helps:

  • Detect new risks associated with drug use.
  • Monitor the safety profile of drugs continuously.
  • Take timely actions to mitigate risks and protect patient safety.
  • Update regulatory authorities and healthcare providers with new safety information.
  • Maintain the benefit-risk balance of medicinal products.

To ensure compliance with regulatory requirements in pharmacovigilance:

  • I stay updated with the latest regulations and guidelines from authorities such as the FDA, EMA, and ICH.
  • I implement standard operating procedures (SOPs) that align with regulatory requirements.
  • I conduct regular audits and reviews to ensure adherence to SOPs.
  • I provide ongoing training and education to the pharmacovigilance team.
  • I maintain accurate and detailed documentation of all pharmacovigilance activities.
  • I promptly report adverse events and safety issues to regulatory authorities as required.

I am familiar with various tools and software used for managing pharmacovigilance data, including:

  • Argus Safety: A widely used pharmacovigilance and safety management system.
  • ARISg: A comprehensive drug safety software for adverse event reporting and analysis.
  • VigiBase: The WHO global database of individual case safety reports.
  • MedDRA (Medical Dictionary for Regulatory Activities): A standardized medical terminology used for coding adverse events.
  • EudraVigilance: The European system for managing and analyzing information on suspected adverse reactions.

If I discovered a serious adverse event in a clinical trial:

  • I would immediately document and report the event to the regulatory authorities and the ethics committee as per regulatory requirements.
  • I would inform the clinical trial sponsor and the principal investigator.
  • I would conduct a thorough investigation to assess the causality and impact on the trial.
  • I would implement necessary actions, such as modifying the trial protocol or halting the trial if needed.
  • I would ensure that participants are informed and that any necessary medical interventions are provided.

I would update the risk assessment and safety monitoring plan for the trial.

To handle the confidentiality of patient information in pharmacovigilance:

  • I adhere to all relevant data protection regulations and guidelines, such as GDPR or HIPAA.
  • I ensure that all patient information is anonymized or de-identified before analysis and reporting.
  • I implement secure data storage and access controls to protect patient data.
  • I provide training to all team members on confidentiality and data protection practices.
  • I regularly review and update data protection policies to ensure ongoing compliance with regulatory requirements.

A Risk Management Plan (RMP) is a detailed document outlining the strategies and actions to identify, assess, minimize, and monitor the risks associated with a medicinal product. It is important because it helps:

  • Ensure that the benefits of a drug outweigh its risks.
  • Provide a structured approach to risk management throughout the product’s lifecycle.
  • Communicate safety information and risk mitigation strategies to healthcare providers and patients.
  • Meet regulatory requirements and enhance public trust in the safety of medicinal products.

Benefit-risk assessment in pharmacovigilance involves evaluating the positive therapeutic effects of a medicinal product against its potential risks and adverse effects. This assessment helps determine whether the benefits of a drug justify its risks and guides decision-making regarding the approval, labeling, and post-marketing surveillance of the product. A continuous benefit-risk assessment ensures that the drug remains safe and effective for patients.

 

When dealing with multiple pharmacovigilance tasks:

  • I assess the urgency and impact of each task on patient safety and regulatory compliance.
  • I prioritize tasks based on deadlines, the severity of safety issues, and the complexity of the tasks.
  • I create a structured plan and set clear goals for each day.
  • I stay organized and manage my time effectively to ensure timely and accurate completion of all tasks.
  • I remain flexible and adjust priorities as needed to accommodate any changes or urgent requests.

Admission Enquiry

Let's chat